Ascendis Pharma A/s

Ascendis Pharma Growth Disorders A/s

Ascendis Pharma Endocrinology Division A/s

Sanofi-a Ventis Deutschland Gmbh

Ascendis Pharma Inc.

Ascendis Pharma Growth Disorders Division A/s

Graffinity Pharmaceuticals Ag

Complex Biosystems Gmbh

Ascendis Pharma Endocrinology Division

Ascendis Pharma Ophthalmology Division A/s

Harald Rau

Ulrich Hersel

Thomas Wegge

Kennett Sprogøe

Felix Cleemann

Dirk Vetter

Nicola Bisek

Torben Lessmann

Susanne Kindermann

Robert Schnepf

Thomas Knappe

Tobias Voigt

Grethe Nørskov Rasmussen

Oliver Keil

Guillaume Maitro

Joachim Zettler

Samuel Weisbrod

Caroline Elisabeth Rasmussen

Burkhardt Laufer

Grethe Norskov Rasmussen

Sebastian Stark

Silvia Kaden-Vagt

Romy Reimann

Kennett Sprogoe

Mathias Krusch

Steen Jensen

Torben Leßmann

Evelyn Exner

Torben Lessman

Alina Hermann

Nina Schubert

Nora Kaluza

Torben Lebmann

Renate Sekul

Kristina Schmidt

Stefan Dickopf

Julia Baron

Thomas Kurpiers

Franziska Hahn

Torben Leβmann

Susanne Kinderman

Ana Bernhard

Silvia Kaden

Felix Cleenmann

Holger Ottleben

Anna Splanemann

Frank Faltinger

Kennett SprogØe

Torben LEßMANN

A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial.

PEGylated recombinant human growth hormone compounds

The present invention relates to hydrogel prodrug compositions comprising cross-linked hyaluronic acid (HA), or a derivative or a salt thereof, wherein the cross-linker system comprises a biodegradable spacer, wherein the cross-linked HA comprises a conjugated drug-linker, and wherein the linker is capable of releasing the drug under physiological conditions. The present invention further relates to methods for preparing the hydrogel prodrug compositions. The present invention further relates to methods for treating an ocular condition using the hydrogel compositions.

Hydrogel cross-linked hyaluronic acid prodrug compositions and methods

The present invention relates to a controlled-release CNP agonist from which CNP agonist is released with a release half-life of at least 6 hours under physiological conditions and which controlled-release CNP agonist has an ECthat is at least 20-fold higher than the ECof the corresponding free CNP agonist and which released CNP agonist has an ECthat is at most 3-fold higher than the ECof the corresponding free CNP agonist; to pharmaceutical compositions comprising said controlled-release CNP agonist; their use; and to methods of treatment.

Controlled-release CNP agonists with low initial NPR-B activity

The present invention relates to dry compositions of rhGH polymer prodrug containing a lyoprotectant and, optionally, one or more than one excipient. Such compositions are stable for at least 1 year, when stored at 2-8° C. The invention further relates to methods of manufacturing said compositions, containers comprising such composition as well as a kit of parts.

Dry growth hormone composition transiently linked to a polymer carrier

The present invention relates to CNP prodrugs in which the carrier is covalently and reversibly attached to the ring moiety of a CNP moiety, to pharmaceutical compositions comprising such CNP prodrugs, to their uses and to methods of treating diseases that can be treated with the CNP prodrugs of the present invention.

CNP prodrugs with carrier attachment at the ring moiety

The present invention relates to a polymeric human growth hormone prodrug and dry, liquid and reconstituted pharmaceutical formulation comprising said prodrug. It furthermore relates to their use as medicaments for the treatment of diseases which can be treated with growth hormone and to methods of treatment. It also relates to methods of application of such polymeric human growth hormone prodrug or pharmaceutical formulation.

Polymeric hGH prodrugs

The present invention relates to controlled-release CNP agonists having an at least 5-fold longer degradation half-life in an in vitro NEP degradation assay than the corresponding released CNP agonist, to pharmaceutical compositions comprising said controlled-release CNP agonist, their use and to methods of treatment.

Controlled-release CNP agonists with increased NEP stability

The present invention relates to novel prodrugs of primary or secondary amine- or hydroxyl-comprising biologically active moieties and pharmaceutically acceptable salts thereof, prodrug reagents, pharmaceutical compositions comprising these prodrugs and the use of these prodrugs. A disclosed prodrug may include a biologically active moiety reversibly and covalently linked to a specialized protective group; the linker may be reversible (i.e., hydrolytically cleavable in the absence of enzymes under physiological conditions) and, upon cleavage, may release a drug in its unmodified, pharmacologically active form.

Prodrugs comprising an aminoalkyl glycine linker

The present invention relates to biodegradable polyethylene glycol based water-insoluble hydrogels comprising backbone moieties which are interconnected by hydrolytically degradable bonds, the backbone moieties further comprising reactive functional groups, wherein the water-insoluble hydrogel is further characterized in that the ratio between the time period for the complete degradation of the hydrogel by hydrolysis of the degradable bonds into water-soluble degradation products comprising one or more backbone moieties and the time period for the release of the first 10 mol-% of water-soluble degradation products comprising one or more backbone moieties based on the total amount of backbone moieties in the hydrogel is greater than 1 and equal to or less than 2. The invention further relates to conjugates of such hydrogels with ligands or ligating groups, prodrugs and pharmaceutical compositions as well as their use in a medicament.

Biodegradable polyethylene glycol based water-insoluble hydrogels

The present invention relates a pharmaceutical composition comprising a controlled-release CNP agonist which reduces CNP agonist-associated side-effects, the use of such controlled-release CNP agonist and to methods of treatment.

Controlled-release CNP agonists with reduced side-effects

The present invention relates to a controlled-release CNP agonist having low NPR-C affinity; to pharmaceutical compositions comprising said controlled-release CNP agonist; their use; and to methods of treatment.

Controlled-release CNP agonists with low NPR-C binding

The present invention relates to novel prodrugs of primary or secondary amine-comprising biologically active moieties and pharmaceutically acceptable salts thereof, prodrug reagents, pharmaceutical compositions comprising said prodrugs and the use of prodrugs.

Prodrugs comprising a pyroglutamate linker

Growing community of inventors

Dossenheim, Germany

Harald Rau